Towards a method for cryopreservation of mosquito vectors of human pathogens

Gallichotte, Emily N.; Dobos, Karen M.; Ebel, Gregory D.; Hagedorn, Mary; Rasgon, Jason L.; Richardson, Jason H.; Stedman, Timothy T.; Barfield, Jennifer P.

doi:10.1016/j.cryobiol.2021.02.001

Cited by 6 publications

(3 citation statements)

References 203 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a significant limitation of traditional slow-cooling techniques is the formation of extracellular ice, which can lead to cooling damage and/or the formation of intracellular ice, resulting in poor viability for larger biological systems. [70][71][72][73] Consequently, for the cryopreservation of organoids, there is a critical need for substantial improvements in existing slow cryopreservation methods.…”

Section: Slow Freezing Of Organoidsmentioning

confidence: 99%

Cryopreservation of organoids: Strategies, innovation, and future prospects

Han,

Zhan,

Guo

et al. 2024

Biotechnology Journal

View full text Add to dashboard Cite

Organoid technology has demonstrated unique advantages in multidisciplinary fields such as disease research, tumor drug sensitivity, clinical immunity, drug toxicology, and regenerative medicine. It will become the most promising research tool in translational research. However, the long preparation time of organoids and the lack of high‐quality cryopreservation methods limit the further application of organoids. Although the high‐quality cryopreservation of small‐volume biological samples such as cells and embryos has been successfully achieved, the existing cryopreservation methods for organoids still face many bottlenecks. In recent years, with the development of materials science, cryobiology, and interdisciplinary research, many new materials and methods have been applied to cryopreservation. Several new cryopreservation methods have emerged, such as cryoprotectants (CPAs) of natural origin, ice‐controlled biomaterials, and rapid rewarming methods. The introduction of these technologies has expanded the research scope of cryopreservation of organoids, provided new approaches and methods for cryopreservation of organoids, and is expected to break through the current technical bottleneck of cryopreservation of organoids. This paper reviews the progress of cryopreservation of organoids in recent years from three aspects: damage factors of cryopreservation of organoids, new protective agents and loading methods, and new technologies of cryopreservation and rewarming.

show abstract

Section: Slow Freezing Of Organoidsmentioning

confidence: 99%

Cryopreservation of organoids: Strategies, innovation, and future prospects

Han,

Zhan,

Guo

et al. 2024

Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…Cryopreservation of mosquitoes generally has proven difficult due largely to characteristics of membrane permeability and chill sensitivity, and no reliable method for cryopreservation of any An. gambiae life stage is yet available ( Gallichote et al, 2023 ). Cryopreservation remains an area of active research and a recent report of success with An.…”

Section: Manufacturing Standardsmentioning

confidence: 99%

Requirements for market entry of gene drive-modified mosquitoes for control of vector-borne diseases: analogies to other biologic and biotechnology products

James

Quemada

Benedict

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Gene drive-modified mosquitoes (GDMMs) are proposed as new tools for control and elimination of malaria and other mosquito-borne diseases, and promising results have been observed from testing conducted in containment. Although still at an early stage of development, it is important to begin now to consider approval procedures and market entry strategies for the eventual implementation of GDMMs in the context of disease control programs, as these could impact future research plans. It is expected that, as for other types of new products, those seeking to bring GDMMs to market will be required to provide sufficient information to allow the regulator(s) to determine whether the product is safe and effective for its proposed use. There already has been much emphasis on developing requirements for the biosafety components of the “safe and effective” benchmark, largely concerned with their regulation as genetically modified organisms. Other potential approval requirements have received little attention, however. Although GDMMs are expected to be implemented primarily in the context of public health programs, any regulatory analogies to other public health products, such as pharmaceuticals, vaccines, or chemical pesticides, must take into account the characteristics of live mosquito products. Typical manufacturing standards related to product identity, potency or quality will need to be adapted to GDMMs. Valuable lessons can be drawn from the regulatory approval processes for other whole organism and genetically modified (GM) organism products. Supply chain requirements, such as scale of production, location and design of production facilities, and methods of distribution and delivery, will be dependent upon the characteristics of the particular GDMM product, the conditions of use, and the region to be served. Plans for fulfilling supply chain needs can build upon experience in the development of other live insect products for use in public health and agriculture. Implementation of GDMMs would benefit from additional research on enabling technologies for long-term storage of mosquito life stages, efficient mass production, and area-wide delivery of GDMMs. Early consideration of these practical requirements for market entry will help to mitigate downstream delays in the development of these promising new technologies.

show abstract

“…Pupae is the resting stage where feeding stops, and the adult mosquito emerges above water after a few days. In the adult stage, female mosquitoes feed from blood to develop eggs [ 7 ] and can acquire the malaria parasite if it feeds from an infected host.…”

Section: Introductionmentioning

confidence: 99%

Tiny Green Army: Fighting Malaria with Plants and Nanotechnology

Moraes-de-Souza,

de Moraes,

Silva

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Malaria poses a global threat to human health, with millions of cases and thousands of deaths each year, mainly affecting developing countries in tropical and subtropical regions. Malaria’s causative agent is Plasmodium species, generally transmitted in the hematophagous act of female Anopheles sp. mosquitoes. The main approaches to fighting malaria are eliminating the parasite through drug treatments and preventing transmission with vector control. However, vector and parasite resistance to current strategies set a challenge. In response to the loss of drug efficacy and the environmental impact of pesticides, the focus shifted to the search for biocompatible products that could be antimalarial. Plant derivatives have a millennial application in traditional medicine, including the treatment of malaria, and show toxic effects towards the parasite and the mosquito, aside from being accessible and affordable. Its disadvantage lies in the type of administration because green chemical compounds rapidly degrade. The nanoformulation of these compounds can improve bioavailability, solubility, and efficacy. Thus, the nanotechnology-based development of plant products represents a relevant tool in the fight against malaria. We aim to review the effects of nanoparticles synthesized with plant extracts on Anopheles and Plasmodium while outlining the nanotechnology green synthesis and current malaria prevention strategies.

show abstract

Towards a method for cryopreservation of mosquito vectors of human pathogens

Cited by 6 publications

References 203 publications

Cryopreservation of organoids: Strategies, innovation, and future prospects

Cryopreservation of organoids: Strategies, innovation, and future prospects

Requirements for market entry of gene drive-modified mosquitoes for control of vector-borne diseases: analogies to other biologic and biotechnology products

Tiny Green Army: Fighting Malaria with Plants and Nanotechnology

Contact Info

Product

Resources

About